HAE · Haemonetics Corp
Price & Indicators
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted earnings per diluted share non-GAAP | $1.14 | 1st Quarter 2027 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Earnings per diluted share $0.72
+$0.16 Amortization of acquired intangible assets
+$0.07 Integration and transaction costs
+$0.04 Restructuring costs
+$0 Restructuring related costs
+$0.1 Digital transformation costs
+$0.01 Litigation-related charges
+$0.02 Equity method losses
+$0.02 Discrete tax items
= Adjusted earnings per diluted share $1.14
|
|||
| Adjusted gross margin non-GAAP | 60.4% | First quarter fiscal 2027 | — |
|
|
|||
| Adjusted operating margin non-GAAP | 23.4% | First quarter fiscal 2027 | — |
|
|
|||
| Free cash flow non-GAAP | $39M | 1st Quarter 2027 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Cash provided by operating activities 52.32M
-7.91M Capital expenditures
-5.57M Additions to Haemonetics equipment
+237K Proceeds from sale of property, plant and equipment
= Free cash flow 39.09M
|
|||
| Organic(1) revenue increase non-GAAP | 5.9% | First Quarter Fiscal 2027 | — |
|
|
|||
| Organic ex-CSL revenue increase non-GAAP | 9.5% | Fiscal 2026 | — |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Devices — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HAE
this stock
Haemonetics Corp
|
$4.93B | +35.3% | -3.0% | — | 6.4% |
|
ABT
Abbott Laboratories
|
$196.27B | -8.7% | +5.7% | 31.6 | 1.3% |
|
SYK
Stryker Corp
|
$127.34B | -3.3% | +11.2% | 34.4 | 2.2% |
|
MDT
Medtronic plc
|
$115.97B | -2.0% | +8.4% | 24.3 | 1.4% |
|
BSX
Boston Scientific Corp
|
$73.14B | -45.5% | +12.5% | 20.4 | 1.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HAE | +18.7% | +38.9% | +74.2% | +26.7% | +35.3% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +19.1% | +36.0% | +62.6% | +23.8% | +22.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.